GlobeImmune, Inc. announced that data from a Phase 2 clinical trial of the GI-4000 Tarmogen® in patients with non-small cell lung cancer (NSCLC) will be presented at the International Association for the Study of Lung Cancer 15th World Conference on Lung Cancer in Sydney, Australia. The study evaluated GI-4000 as consolidation therapy in patients with tumors with mutations in K-Ras following treatment with curative intent for Stage I-III NSCLC. The study was performed at Memorial Sloan Kettering Cancer Center (MSKCC) in New York.

In this study, 24 patients with Stage I-III, K-Ras mutant+ NSCLC who successfully completed first-line treatment were enrolled in the study. Additionally, 64 case-matched, contemporary control patients were followed at MSKCC. GI-4000-treated patients demonstrated a trend for improved 1-, 2- and 3-year survival over the case-matched controls.